Save Product
Product Details
Materials Provided
IDComponentsSizeEP159-C01High-bind Plate1 plateEP159-C02Human IL-1155 μgEP159-C03Biotinylated Human IL-11R20 μgEP159-C04Anti-IL-11 Neutralizing Antibody20 μgEP159-C05Streptavidin-HRP5 μgEP159-C06Coating Buffer12 mLEP159-C0710xWashing Buffer50 mLEP159-C08Blocking Buffer50 mLEP159-C09Substrate Solution12 mLEP159-C10Stop Solution7 mLProduct Overview
IL-11 : IL-11R [Biotinylated] Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human IL-11 binding to human IL-11R. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human IL-11 binding to human IL-11R.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
Unopened kit should be stored at 2°C-8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.
INHIBITION OF IL-11: IL-11R [Biotinylated] BINDING BY ANTI-IL-11 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-IL-11 Neutralizing antibody (Catalog # EP159-C04) (1:1 serial dilution, from 10 μg/mL to 0.0195μg/mL) was added into IL-11: Biotinylated IL-11R binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
Interleukin-11
- Category：
- Approved Drugs：
1 Details
- Drugs in Clinical Trials：
3 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
